Aims: SARC-F ≥ 4 points are used for detecting sarcopenia; however, finding a lower SARC-F cut-off value may lead to early detection of sarcopenia. We investigated the SARC-F score with the highest sensitivity and specificity values to identify sarcopenia in older patients with cardiovascular disease (CVD). Motor performances were also examined for each SARC-F score. Methods and results: This retrospective cross-sectional study examined the sensitivity and specificity of every 1-point increase in the SARC-F score to predict sarcopenia. Eligible participants included patients with CVD (≥65 years old) who were admitted for acute CVD treatment and participated in cardiac rehabilitation. Patients completed the SARC-F questionnaire and the sarcopenia assessment. Area under the curves (AUCs) were investigated for the ability to predict sarcopenia. Multivariable linear regression was used to compare the mean value of physical functions (e.g. walking speed, leg strength, and 6 min walking distance) of each SARC-F score. A total of 1066 participants (63.8% male; median age: 76 years) were included. Sarcopenia was present in 401 patients. A SARC-F cut-off ≥2 presented the optimal balance between sensitivity (68.3%) and specificity (55.6%) to detect sarcopenia (AUCs = 0.658; 95% confidence interval: 0.625–0.691). When the patients had low scores (1–3), every 1 point increase in the SARC-F score was associated with lower physical functions such as lower muscle strength and shorter walking distance (all P < 0.001). Conclusion: A SARC-F cut-off ≥2 was optimal for screening sarcopenia, and even a low SARC-F score is useful in detecting sarcopenia and low physical function at an early stage in patients with CVD.
19 June 2026 in European Journal of Cardiovascular Nursing
Background: Cancer and cardiovascular disease (CVD) share common risk factors, and the development of CVD in cancer survivors is a significant event that worsens prognosis. Comprehensive cardiac rehabilitation (CR) has been reported to be associated with improved prognosis, including risk of death and rehospitalisation, in patients with CVD. However, the benefits of CR to patients with both cancer and CVD is unclear. Aims: This study aimed to investigate the usefulness of CR in CVD patients with cancer history. Methods: We retrospectively reviewed 1,424 CVD patients with a cancer history (median age: 76 [69–81] years). Primary and secondary outcomes were all-cause mortality and composite events of all-cause death and CVD-related rehospitalisation, respectively. CR participation was defined as attending rehabilitation at least once within three months of discharge. We performed propensity score (PS) matching for CR, followed by Cox regression analysis, to assess the association between CR and prognosis. Results: During the median follow-up period of 1.8 (0.7–3.4) years, 286 deaths and 465 composite events occurred. After PS matching, 1,008 patients (504 pairs) were included, with standardised mean differences of < 0.1 for all covariates. CR participation was associated with a significantly lower risk of all-cause mortality (Hazard ratio [HR]: 0.54, 95% confidence interval [CI]: 0.41–0.73, P < 0.001) and composite event rates (HR: 0.62, 95% CI: 0.50–0.78, P < 0.001) compared to CR non-participation. Conclusion: CR participation was associated with a lower risk of poor prognostic events in CVD patients with a history of cancer.
14 May 2026 in European Journal of Cardiovascular Nursing
Aims: The FRAIL scale questionnaire is a brief measure of physical frailty in patients with cardiovascular disease (CVD); however, its performance in those with concomitant cognitive impairment remains uncertain. We investigated the accuracy of the FRAIL scale in identifying physical frailty defined by the Fried criteria and its association with adverse events in older patients with CVD and cognitive decline. Methods and results: This retrospective cohort study comprised 318 patients (male, 66.7%; median age, 79 years) with CVD (≥60 years old) who had cognitive impairment (Mini-Cog <3 points) and completed the FRAIL scale. The accuracy of the FRAIL scale for identifying physical frailty was evaluated using the area under the curve (AUC). Associations with frailty, motor functions (e.g. leg strength, walking speed, 6-min walk test distance), and prognosis was tested using multivariable regression models and survival analysis. The AUC for predicting physical frailty was 0.749 (95% confidence interval [CI], 0.697–0.801). Higher FRAIL scale scores were associated with physical frailty (adjusted odds ratio, 2.087; 95% CI, 1.647–2.645) and motor function decline (all P < 0.05). During follow-up (median, 335 days), 70 patients experienced the first composite event (all-cause death or cardiovascular rehospitalization). Frailty assessed by the FRAIL scale was associated with higher composite event rates (adjusted hazard ratio, 1.918; 95% CI, 1.134–3.243). Conclusion: In older patients with CVD and cognitive decline, higher FRAIL scale scores are associated with objectively assessed physical frailty and worse prognosis. These findings indicate that the FRAIL scale questionnaire is applicable for frailty screening and risk stratification in this population.
16 October 2026 in European Journal of Cardiovascular Nursing